A girl, second child of healthy parents, was referred to the Renal Unit at the age of 9 months with haematuria (230 RBC/µl) and proteinuria (2.4 g/l). Serum creatinine was normal (0.25 mg/dl), albumin low (34 g/l) and cholesterol elevated (223 mg/dl). Physical examination showed bilateral webbing of the elbows, equinovarus of both feet and absent patellae. The clinical diagnosis of nail-patella syndrome was confirmed by demonstrating a splice mutation in the intron 5 (750 + 1 G>A) of the LMX1B gene. Treatment with enalapril for 2 years (0.1-1 mg/kg per day) did not bring about any change in urinary protein excretion. However, enalapril (1 mg/kg per day) associated with losartan (1 mg/kg per day) resulted in complete remission (proteinuria 140 mg/24 h) at the age of 7 years.
Introduction
The Nail Patella syndrome (NPS), also referred to as Hereditary Onycho-osteodysplasia (OMIM 161 200), is a dominantly inherited disorder caused by mutations of the LMX1B gene that encodes the NPS protein, a transcription factor involved in limb, eye and renal development [1] . Dysplasia of the nails and absence or hypoplasia of the patellae are the cardinal features. Additional anomalies are iliac horns, abnormalities of the elbows, the eyes and the glomeruli. The Glomerular disease, which is found in about one-third of the patients, consists of haematuria with or without proteinuria; the nephrotic syndrome is exceptional and progression to end-stage renal failure is possible. Renal histology shows the presence of collagen fibrils causing thickening of the glomerular basement membrane [2] . Nephropathy is the most severe asCorrespondence and offprint requests to: Willem Proesmans, University Hospital Gasthuisberg, 3000 Leuven, Belgium. Tel: +32-16-34-21-51; Fax: +32-16-34-21-52; E-mail: willem.proesmans@med.kuleuven.be pect of the disease, and there is no specific treatment. We report here the successful antiproteinuric treatment of an NPS patient who presented with infantile nephrotic syndrome.
Case report
A girl, second child of healthy unrelated parents, presented at birth with bilateral elbow contractures and bilateral partially reducible foot equinovarus. Pregnancy had been reportedly uncomplicated. Delivery occurred spontaneously at term. Birth weight was 3320 g, length 49 cm and head circumference 35 cm. The baby was able to move the four limbs spontaneously. She fed well and gained weight as expected. At the age of 3 months, EMG recordings were interpreted as suggestive of spinal muscular atrophy and a brain MRI did not reveal any anomaly. Orthopaedic surgery was successful in correcting the baby's feet malposition.
Nephropathy
At the age of 9 months, urinalysis, carried out because of high fever, showed no infection but haematuria and proteinuria. She was referred to us. The baby was not ill looking but rather thin without oedema. The body weight was 8.14 kg, length 73 cm and blood pressure 92/52 mmHg. Physical examination revealed two striking anomalies: bilateral antecubital pterygium with marked limitation of arm extension and the absence of patellae. A urine sample contained 230 RBC/µl (normal values <5) and a protein/creatinine ratio of 7.3 g/g (normal value < 0.2). Serum creatinine was 0.25 mg/dl, albumin 34 g/l (normal values 35-45 g/l) and cholesterol 223 mg/dl (normal values <180 mg/dl). Serum total complement and C3 levels were within the normal range. Inulin clearance was 110 ml/min/1.73 m 2 . A renal biopsy specimen contained 18 glomeruli; glomeruli, tubuli, vascular structures and interstitium were reported as normal as was the immunohistochemistry. Electron microscopy revealed a thin GMB with marked fusion of the podocytes. 
Genetic investigation
DNA of the patient and her parents was examined for mutations of the LMX1B gene. In the girl, a mutation was found and identified as 750 + 1G>A. Both parents were screened for this mutation by sequence analysis of exon 5 of the LMX1B gene; the analysis did not reveal this mutation in the parents. It was concluded that the mutation most likely arose de novo in our patient.
Treatment
Treatment with enalapril was started at the age of 12 months at a dose of 0.1 mg/kg, which is low because of the patient's normal blood pressure. The dose of the drug was gradually increased over the next 18 months to 1 mg/kg per day. Treatment was well tolerated, but no change in proteinuria was observed. Plasma renin activity (PRA) increased over time, as expected: from 4.3 ng/ml/h at the start of the treatment to 29 and 27 ng/ml/h after 1 year and 18 months of treatment, respectively. The plasma aldosterone concentration (PAC) before the treatment was 137 ng/dl but remained almost unchanged with 158 ng/dl after 18 months of therapy with the ACE inhibitor. Inulin clearance was 135 ml/min/1.73 m 2 and 139 ml/min/1.73 m 2 after 1 and 2 years of treatment, respectively. At this time the child was still nephrotic (serum albumin 30 g/l, cholesterol 225 mg/dl).
The therapy was changed: after 2 years, 12.5 mg of losartan was added to 12.5 mg of enalapril, both dosages corresponding roughly to 1 mg/kg per day. The therapy was well tolerated, and the Uprot/creat ratio dropped from 7.2 g/g to 0.63 g/g and 0.38 g/g after 6 and 12 months, respectively ( Figure 1 ). The dose of enalapril was kept unchanged, and the dose of losartan was increased to 1 mg/kg per day. PRA increased to a maximum of 85 ng/ml/h, and PAC dropped to a minimum of 78 ng/dl.
At the age of 6 years, after 5 years of the combined antiproteinuric treatment, the following observations were made: body length 112 cm (P25), body weight 16 kg (P3), blood pressure 80/51 mmHg. The urine protein/creatinine ratio of 0.45 g/g and creatinine clearance measured with a 24 h urine collection 75 ml/min/1.73 m 2 . At the age of 7 years, after 6 years of therapy, proteinuria had fallen to 0.140 g per 24 h, which is in the normal range while serum creatinine was 0.48 mg/dl and the creatinine clearance 84 ml/min/1.73 m 2 .
Discussion
The nail-patella syndrome (NPS) as a clinical entity was described by Aschner in 1934 [3] . It is a dominantly inherited disease involving several organs including the skeleton, the eyes, the ears and the kidneys. The incidence is estimated at 1/50 000 live births. Dreyer et al. demonstrated in 1998 that mutations of the LMX1B gene are responsible for NPS. LMX1B is a transcription factor involved in limb, eye and renal development [4] . For review of both the clinical and genetic characteristics, the reader is referred to two recent papers by Meyrier et al. [2] and by Bongers et al. [1] . More than 100 mutations have been reported so far that are more or less evenly distributed among the three major domains of the gene: LIMA, LIMB and the homeodomain. Bongers et al. [5] analysing the genotype-phenotype relationship came to following conclusions: (i) Nephropathy is more frequent in females and (ii) patients with mutations located in the homeodomain have statistically significant higher proteinuria than subjects carrying mutations in the LIM domains. Accordingly, our patient, a girl with a mutation in the homeodomain, belongs to the high-risk group. The 750 + 1 G>A mutation detected in our patient has been described before by Seri et al. [6] . The splice mutation in the donor splice site is expected to result in the loss of exon 5 containing part of the homeodomain. NPS nephropathy is a glomerular disease of both the glomerular basement membrane and the podocyte. The study of the LMX1B knockout mice demonstrated the essential role of the LMX1B protein for the development of metanephric precursor cells into podocytes; hence, NPS nephropathy is another example of podocytopathy. An excellent recent review on the podocyte and NPS is available [7] . NPS nephropathy is the most severe aspect of the disease. The natural history has not been described in detail, and there is little information on paediatric patients. It is generally accepted that only one-third of the affected individuals have renal disease and <15% of them develop end-stage renal disease (ESRD). In review papers, NPS is often listed among the causes of congenital and infantile nephrotic syndrome [8] . However, precise information on individual patients is scarce.
Similä et al. reported a newborn baby with NPS and a nephrotic syndrome that recovered spontaneously within 2 weeks [9] . The presence of the classical phenotype and the family history are definitely in favour of NPS. However, the course of the illness with a long-lasting remission is unlikely to be genuine NPS nephropathy. A renal biopsy was not performed for obvious reasons.
Sabnis et al. described, under the heading NPS, three patients, the youngest one an 8-year-old boy with the nephrotic syndrome [10] . Renal histology, including electron microscopy, showed lesions identical to those seen in NPS. Follow-up data are lacking. The patient did not display any extra-renal anomaly. It is therefore likely that he suffered from the nail-patella-like renal disease, nowadays referred to as collagen type III glomerulopathy, an autosomal recessive disorder in its own right (OMIM 256020) [11] .
Hari et al. observed a steroid responsive, frequently relapsing nephrotic syndrome in an NPS patient [12] . Renal histology showed minimal lesions but ultrastructural features of NPS. This is probably a coincidence of two different disorders occurring in one patient. The same applies to the 7-year-old NPS patient with IgA nephropathy reported by Gao et al. [13] .
The only patient our patient can be compared with is the French boy, cited in Bongers et al.'s 2002 paper [1] , with proteinuria from birth, nephrotic syndrome at the age of 4 years and ESRD at the age of 7 years. This is a classical story of progression of proteinuric nephropathy. Our patient behaved differently, and it is tempting to ascribe this better course to the treatment.
There is no treatment for most genetic nephropathies leading to ESRD but renal transplantation. However, in proteinuric nephropathies, both genetic and acquired, progression can be slowed by blocking the renin-angiotensinaldosteron system (RAAS). For this goal especially angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) are used. Results with ACEI are most impressive in adults with diabetic nephropathy as an example of the acquired nephropathies [14, 15] . Several studies in paediatric patients showed satisfactory short-term results of these antiproteinuric drugs in patients with diabetes mellitus [16] , steroid resistant nephrotic syndrome [17] , reflux nephropathy [18] and chronic renal failure due to renal hypo-dysplasia [19] . One long-term study in former HUS patients with renal sequelae suggests effective renal protection [20] . There are also some reports on the renoprotective effects of ACEI in two hereditary glomerulopathies, the congenital nephrotic syndrome [21] and Alport syndrome [22] .
Treatment with the ACEI enalapril was not effective in our patient. The marked increase of PRA indicates compliance, and the stable PAC suggests insufficient blockade of aldosterone production. When enalapril was combined with losartan, an ARB, a rapid and sustained reduction of proteinuria was observed resulting in complete remission at the age of 7 years while serum creatinine and creatinine clearance remained within the normal range. The results were accompanied by a further increase of PRA and a more efficient blockade of aldosterone production.
The literature has scarce information on the combined ACEI + ARB therapy in human renal diseases. A recent metanalysis of the results in adult diabetic nephropathy [23] concludes that 'the combination of ACEI and ARBs further reduces proteinuria more than either agent alone'. There are two reports on paediatric patients with IgA nephropathy in whom the antiproteinuric effect was significantly better with the combined therapy than with the ACEI alone [24, 25] .
To the best of our knowledge, our report provides the first demonstration that the combined RAAS suppression therapy yields a complete remission in a child with an infantile nephrotic syndrome due to NPS nephropathy.
The important question why our patient had such an early and severe nephropathy remains unanswered. Renal manifestations in NPS are highly variable and unpredictable. This points to the existence of modifiers that could be either genetic or environmental or both. Currently, the only genetic modifier known to confer an increased risk for renal disease in NPS is the location of the mutation in the homeodomain. Additional genetic and environmental modifiers must exist. Polymorphisms in genes causing congenital nephrotic syndrome are possible candidate modifiers. However, the probability of both conditions occurring in the same individual is ∼1/2 000 000.
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Congenital nephrotic syndrome of the Finnish type (CNF) is a rare autosomal recessive disease due to mutations in the
